



JIAN-GUO ZHOU

Phone: +86-18311543939
 jianguo.zhou@zmu.edu.cn

Intersection Of Xinlong And Xinpu Avenue
 Zunyi, China 563000

EDUCATION

- PhD candidate** University of Erlangen-Nuremberg, Germany, Radiation Oncology May 2022
 Dissertation: "Identification and validation of immune biomarkers of the peripheral blood for cancer patients receiving radio(chemo)therapy and/or immunotherapy"
 Advisor: Prof. Dr. Udo Gaipl
- MS** Zunyi Medical University, China, Thoracic Oncology July 2017
 Thesis: "Hsa-miR-125a-5p reverses the resistance of NSCLC-TKIs through Rab25/PI3K/AKT signaling pathway"
 Advisor: Prof. Dr. Hu Ma
 Graduated Summa Cum Laude
- MD** Northwest Minzu University, China, Clinical Medicine July 2014

GRANTS AND AWARDS

- ESMO IO 2021 Travel Grant** 2021
 ESMO offered a grant of 1000 Euro for accommodation and travel costs.
- KSMO 2020 Young Investigator Award** 2020
 The Awards, worth USD 500 each, are awarded to researchers who submit abstracts to KSMO.
- ESMO Asia 2019 Merit Award** 2019
 The organisers provided the recipients with a subsidised travel ticket, subsidised accommodation and Congress registration.
- CSCO Young Oncologist Award (35 under 35)** 2019
 The organisers selected 35 recipients under the age of 35 whom focus on cancer researches in China.
- ESMO Asia 2018 Merit Award** 2018
 The organisers provided the recipients with a subsidised travel ticket, subsidised accommodation and Congress registration.



Grant/Funding (PI: Jian-Guo Zhou)

Title	Promotional Institution	Duration	Sum [RMB]
Identification and validation of a Prognostic Signature in Oral Cancer	the Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, No.05	02/2018–02/2020	20,000
Identification and validation of Immune related Prognostic Models in Oral Squamous Cell Carcinoma	Research Programs of Health Commission Foundation of Guizhou Province, gzwjkj2019-1-073	09/2019 – 08/2021	20,000
Long noncoding RNA MALAT1 promotes Invasion and Metastasis via the FGF23 / β -catenin pathway-mediated EMT in Uterine Sarcoma	National Natural Science Foundation of China (Grant No. 81660512)	01/2021–12/2024	340,000
Based on machine learning methods to explore the role of multi-omics as predictor for NSCLC treated with third-generation EGFR-TKIs	Lian Yun Gang Shi Hui Lan Public Foundation (Grant No. HL-HS2020-92)	01/2021–12/2023	50,000

PUBLICATIONS

List your publications in reverse chronological order. Use an acceptable reference format commonly used in your field. Group your publications into different categories if you have a sufficient number to do so.

Journal Publications

1. Zhou, J.G.; Liang, B.; Liu, J.G.; Jin, S.H.; He, S.S.; Frey, B.; Gu, N.; Fietkau, R.; Hecht, M.; Ma, H., et al. Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. *Cells* 2021, 10, doi:10.3390/cells10050977.
2. Zhou, J.G.; Donaubauer, A.J.; Frey, B.; Becker, I.; Rutzner, S.; Eckstein, M.; Sun, R.; Ma, H.; Schubert, P.; Schweizer, C., et al. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. *Journal for immunotherapy of cancer* 2021, 9, doi:10.1136/jitc-2020-001845.
3. Zhou, J.-G.; Huang, Z.; Slaby, O.; Navarro, A. The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility. *Frontiers in Oncology* 2021, 10, 3351.

Virtual Mentorship



4. Zhong, H.; Liu, S.; Cao, F.; Zhao, Y.; Zhou, J.; Tang, F.; Peng, Z.; Li, Y.; Xu, S.; Wang, C., et al. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine. *Frontiers in immunology* 2021, 12, 709986, doi:10.3389/fimmu.2021.709986.
5. Yu, Y.; Zeng, Y.; Xia, X.; Zhou, J.G.; Cao, F. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma. *Cancer control : journal of the Moffitt Cancer Center* 2021, 28, 10732748211033751, doi:10.1177/10732748211033751.
6. Semrau, S.; Gostian, A.O.; Traxdorf, M.; Eckstein, M.; Rutzner, S.; von der Grün, J.; Illmer, T.; Hautmann, M.; Klautke, G.; Laban, S., et al. Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. *Cancers* 2021, 13, doi:10.3390/cancers13081959.
7. Ma, S.C.; Tang, X.R.; Long, L.L.; Bai, X.; Zhou, J.G.; Duan, Z.J.; Wang, J.; Fu, Q.J.; Zhu, H.B.; Guo, X.J., et al. Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. *Oncoimmunology* 2021, 10, 1909296, doi:10.1080/2162402x.2021.1909296.
8. Griewing, L.M.; Schweizer, C.; Schubert, P.; Rutzner, S.; Eckstein, M.; Frey, B.; Haderlein, M.; Weissmann, T.; Semrau, S.; Gostian, A.O., et al. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. *BMC cancer* 2021, 21, 314, doi:10.1186/s12885-021-08006-0.
9. Zhou, R.H.; Chen, C.; Jin, S.H.; Li, J.; Xu, Z.H.; Ye, L.; Zhou, J.G. Co-expression gene modules involved in cisplatin-induced peripheral neuropathy according to sensitivity, status, and severity. *Journal of the peripheral nervous system : JPNS* 2020, 25, 366-376, doi:10.1111/jns.12407.
10. Zhou, J.G.; Yang, J.; Jin, S.H.; Xiao, S.; Shi, L.; Zhang, T.Y.; Ma, H.; Gaipl, U.S. Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors. *Front Oncol* 2020, 10, 1147, doi:10.3389/fonc.2020.01147.
11. Zhou, J.G.; Huang, Z.; Slaby, O.; Navarro, A. Editorial: The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility. *Front Oncol* 2020, 10, 631316, doi:10.3389/fonc.2020.631316.
12. Zhou, J.G.; Huang, L.; Jin, S.H.; Xu, C.; Frey, B.; Ma, H.; Gaipl, U.S. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. *ESMO open* 2020, 5, doi:10.1136/esmoopen-2019-000621.
13. Schweizer, C.; Schubert, P.; Rutzner, S.; Eckstein, M.; Haderlein, M.; Lettmaier, S.; Semrau, S.; Gostian, A.O.; Frey, B.; Gaipl, U.S., et al. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. *European journal of cancer (Oxford, England : 1990)* 2020, 140, 55-62, doi:10.1016/j.ejca.2020.09.001.
14. Schubert, P.; Rutzner, S.; Eckstein, M.; Frey, B.; Schweizer, C.; Haderlein, M.; Lettmaier, S.; Semrau, S.; Gostian, A.O.; Zhou, J.G., et al. Prospective Evaluation of All-lesion Versus Single-lesion



Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors. *Front Oncol* 2020, 10, 576643, doi:10.3389/fonc.2020.576643.

15. Jin, S.H.; Zhou, R.H.; Guan, X.Y.; Zhou, J.G.; Liu, J.G. Identification of novel key lncRNAs involved in periodontitis by weighted gene co-expression network analysis. *Journal of periodontal research* 2020, 55, 96-106, doi:10.1111/jre.12693.
16. Jin, S.H.; Zhou, J.G.; Guan, X.Y.; Bai, G.H.; Liu, J.G.; Chen, L.W. Development of an miRNA-Array-Based Diagnostic Signature for Periodontitis. *Frontiers in genetics* 2020, 11, 577585, doi:10.3389/fgene.2020.577585.
17. Donaubaue, A.J.; Zhou, J.G.; Ott, O.J.; Putz, F.; Fietkau, R.; Keilholz, L.; Gaipl, U.S.; Frey, B.; Weissmann, T. Low Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis. *International journal of molecular sciences* 2020, 21, doi:10.3390/ijms21165854.
18. Zhou, J.G.; Zhong, H.; Zhang, J.; Jin, S.H.; Roudi, R.; Ma, H. Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma. *Front Oncol* 2019, 9, 78, doi:10.3389/fonc.2019.00078.
19. Zhou, J.G.; Zhao, H.T.; Jin, S.H.; Tian, X.; Ma, H. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma. *Gynecologic oncology* 2019, 155, 499-507, doi:10.1016/j.ygyno.2019.08.033.
20. Zhou, J.G.; Liang, B.; Jin, S.H.; Liao, H.L.; Du, G.B.; Cheng, L.; Ma, H.; Gaipl, U.S. Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma. *Front Oncol* 2019, 9, 1361, doi:10.3389/fonc.2019.01361.
21. Xu, C.; Liu, Y.; Zhang, C.; Kwong, J.S.W.; Zhou, J.G.; Ge, L.; Huang, J.Y.; Liu, T.Z. An overview on the methodological and reporting quality of dose-response meta-analysis on cancer prevention. *Journal of cancer research and clinical oncology* 2019, 145, 1201-1211, doi:10.1007/s00432-019-02869-4.
22. Luo, P.; Zhou, J.G.; Jin, S.H.; Qing, M.S.; Ma, H. Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database. *Journal of ovarian research* 2019, 12, 126, doi:10.1186/s13048-019-0600-7.
23. Zhou, J.G.; Zhou, N.J.; Zhang, Q.; Feng, Y.Y.; Zhou, H. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. *Trials* 2018, 19, 500, doi:10.1186/s13063-018-2858-2.
24. Wang, X.; Zhou, J.; Xu, M.; Yan, Y.; Huang, L.; Kuang, Y.; Liu, Y.; Li, P.; Zheng, W.; Liu, H., et al. A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer. *Cancer management and research* 2018, 10, 5799-5806, doi:10.2147/cmar.S178732.
25. Fathi, Z.; Syn, N.L.; Zhou, J.G.; Roudi, R. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. *Journal of human genetics* 2018, 63, 783-794, doi:10.1038/s10038-018-0450-y.
26. Zhang, X.; Zhou, J.G.; Wu, H.L.; Ma, H.; Jiang, Z.X. Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis. *Oncotarget* 2017, 8, 75400-75410, doi:10.18632/oncotarget.17914.

27. Song, G.M.; Tian, X.; Liu, X.L.; Chen, H.; Zhou, J.G.; Bian, W.; Chen, W.Q. Concurrent chemoradiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis. *Oncotarget* 2017, 8, 37963-37973, doi:10.18632/oncotarget.16302.
28. Lv Sh, P.; Wang, Y.; Huang, L.; Wang, F.; Zhou, J.G.; Ma, H. Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer. *Asian Pacific journal of cancer prevention : APJCP* 2017, 18, 391-397, doi:10.22034/apjcp.2017.18.2.391.
29. Huang, L.; Zhou, J.G.; Zhang, Y.; Wang, F.; Wang, Y.; Liu, D.H.; Li, X.J.; Lv, S.P.; Jin, S.H.; Bai, Y.J., et al. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Journal of pain and symptom management* 2017, 54, 737-748.e733, doi:10.1016/j.jpainsymman.2017.07.025.
30. Huang, L.; Zhou, J.G.; Yao, W.X.; Tian, X.; Lv, S.P.; Zhang, T.Y.; Jin, S.H.; Bai, Y.J.; Ma, H. Systematic review and meta-analysis of the efficacy of serum neuron-specific enolase for early small cell lung cancer screening. *Oncotarget* 2017, 8, 64358-64372, doi:10.18632/oncotarget.17825.
31. Ge, L.; Pan, B.; Song, F.; Ma, J.; Zeraatkar, D.; Zhou, J.; Tian, J. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. *BMJ open* 2017, 7, e018175, doi:10.1136/bmjopen-2017-018175.
32. Zhou, Q.; Li, H.; Zhou, J.G.; Ma, Y.; Wu, T.; Ma, H. Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis. *Archives of gynecology and obstetrics* 2016, 293, 143-155, doi:10.1007/s00404-015-3811-1.
33. Song, G.M.; Tian, X.; Jin, Y.H.; Deng, Y.H.; Zhang, H.; Pang, X.L.; Zhou, J.G. Moxibustion is an Alternative in Treating Knee Osteoarthritis: The Evidence From Systematic Review and Meta-Analysis. *Medicine* 2016, 95, e2790, doi:10.1097/md.0000000000002790.
34. Song, G.M.; Deng, Y.H.; Jin, Y.H.; Zhou, J.G.; Tian, X. Meta-analysis comparing chewing gum versus standard postoperative care after colorectal resection. *Oncotarget* 2016, 7, 70066-70079, doi:10.18632/oncotarget.11735.
35. Song, G.M.; Bian, W.; Zeng, X.T.; Zhou, J.G.; Luo, Y.Q.; Tian, X. Laparoscopic cholecystectomy for acute cholecystitis: early or delayed?: Evidence from a systematic review of discordant meta-analyses. *Medicine* 2016, 95, e3835, doi:10.1097/md.0000000000003835.
36. Ma, H.; Yao, W.X.; Huang, L.; Jin, S.H.; Liu, D.H.; Liu, Y.; Tian, X.; Tian, J.H.; Zhou, J.G. Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis. *Oncotarget* 2016, 7, 70128-70142, doi:10.18632/oncotarget.11806.
37. Ma, H.; Tian, X.; Zeng, X.T.; Zhang, Y.; Wang, Y.; Wang, F.; Zhou, J.G. The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis. *Medicine* 2016, 95, e2495, doi:10.1097/md.0000000000002495.

38. Ma, H.; Liu, Y.; Huang, L.; Zeng, X.T.; Jin, S.H.; Yue, G.J.; Tian, X.; Zhou, J.G. The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine* 2016, 95, e3341, doi:10.1097/md.0000000000003341.
39. Liu, W.; Zhou, J.G.; Sun, Y.; Zhang, L.; Xing, B.C. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis. *Oncotarget* 2016, 7, 37277-37287, doi:10.18632/oncotarget.8671.
40. Li, Y.; Yang, Z.; Wan, X.; Zhou, J.; Zhang, Y.; Ma, H.; Bai, Y. Clinical prognostic value of metastasis-associated lung adenocarcinoma transcript 1 in various human cancers: an updated meta-analysis. *The International journal of biological markers* 2016, 31, e173-182, doi:10.5301/ijbm.5000185.
41. Guo, P.; Xu, C.; Zhou, Q.; Zhou, J.; Zhao, J.; Si, Z.; Shen, C.; Feng, C. Number of parity and the risk of gallbladder cancer: a systematic review and dose-response meta-analysis of observational studies. *Archives of gynecology and obstetrics* 2016, 293, 1087-1096, doi:10.1007/s00404-015-3896-6.
42. Fu, S.; Li, F.; Zhou, J.; Liu, Z. The Relationship Between Body Iron Status, Iron Intake And Gestational Diabetes: A Systematic Review and Meta-Analysis. *Medicine* 2016, 95, e2383, doi:10.1097/md.0000000000002383.
43. Zhou, Q.; Luo, M.L.; Li, H.; Li, M.; Zhou, J.G. Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. *Scientific reports* 2015, 5, 13410, doi:10.1038/srep13410.
44. Zhou, J.G.; Tian, X.; Wang, X.; Tian, J.H.; Wang, Y.; Wang, F.; Zhang, Y.; Ma, H. Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. *Medical oncology (Northwood, London, England)* 2015, 32, 471, doi:10.1007/s12032-014-0471-0.
45. Zhou, J.G.; Tian, X.; Cheng, L.; Zhou, Q.; Liu, Y.; Zhang, Y.; Bai, Y.J.; Ma, H. The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis. *Medicine* 2015, 94, e1719, doi:10.1097/md.0000000000001719.
46. Wang, F.; Zhou, J.; Zhang, Y.; Wang, Y.; Cheng, L.; Bai, Y.; Ma, H. The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis. *PloS one* 2015, 10, e0136889, doi:10.1371/journal.pone.0136889.
47. Tian, X.; Zhou, J.G.; Zeng, Z.; Shuai, T.; Yi, L.J.; Ma, L.; Wang, Y.; Cao, H.; Song, G.M. Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. *Medical oncology (Northwood, London, England)* 2015, 32, 127, doi:10.1007/s12032-015-0521-2.
48. Tian, X.; Yi, L.J.; Zhang, L.; Zhou, J.G.; Ma, L.; Ou, Y.X.; Shuai, T.; Zeng, Z.; Song, G.M. Oral Motor Intervention Improved the Oral Feeding in Preterm Infants: Evidence Based on a Meta-Analysis With Trial Sequential Analysis. *Medicine* 2015, 94, e1310, doi:10.1097/md.0000000000001310.
49. Song, G.M.; Tian, X.; Zhang, L.; Ou, Y.X.; Yi, L.J.; Shuai, T.; Zhou, J.G.; Zeng, Z.; Yang, H.L. Immunonutrition Support for Patients Undergoing Surgery for Gastrointestinal Malignancy: Preoperative, Postoperative, or Perioperative? A Bayesian Network Meta-Analysis of Randomized Controlled Trials. *Medicine* 2015, 94, e1225, doi:10.1097/md.0000000000001225.



50. Song, G.M.; Tian, X.; Shuai, T.; Yi, L.J.; Zeng, Z.; Liu, S.; Zhou, J.G.; Wang, Y. Treatment of Adults With Treatment-Resistant Depression: Electroconvulsive Therapy Plus Antidepressant or Electroconvulsive Therapy Alone? Evidence From an Indirect Comparison Meta-Analysis. *Medicine* 2015, 94, e1052, doi:10.1097/md.0000000000001052.
51. Song, G.M.; Tian, X.; Liang, H.; Yi, L.J.; Zhou, J.G.; Zeng, Z.; Shuai, T.; Ou, Y.X.; Zhang, L.; Wang, Y. Role of Enteral Immunonutrition in Patients Undergoing Surgery for Gastric Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine* 2015, 94, e1311, doi:10.1097/md.0000000000001311.
52. Liu, W.; Zhou, J.G.; Xing, B.C. Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma: a Letter to Response. *Journal of gastrointestinal surgery* 2015, 19, 2290-2291, doi:10.1007/s11605-015-2966-1.

Journal Papers in Review

1. Jian-Guo Zhou, Ada Hang-Heng Wong, Haitao Wang, Su-Han Jin, Fangya Tan, Yu-Zhong Chen, Si-Si He, Gang Shen, Benjamin Frey, Rainer Fietkau, Markus Hecht, Shamus R. Carr, Ruihong Wang, Bo Shen, David S Schrupp, Hu Ma, Udo S. Gaipl. doi: <https://doi.org/10.1101/2021.08.28.21262770>

Conference Abstracts

1. Zhou, J.; Donaubaue, A.; Frey, B.; Becker, I.; Rutzner, S.; Sun, R.; Ma, H.; Fietkau, R.; Deutsch, E.; Gaipl, U., et al. P14.16 The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors. *Journal of Thoracic Oncology* 2021, 16, S336, doi:10.1016/j.jtho.2021.01.522. (WCLC 2021)
2. Weissmann, T.; Putz, F.; Hecht, M.; Zhou, J.-G.; Donaubaue, A.-J.; Fietkau, R.; Gaipl, U.; Ott, O.; Benjamin, F. Low-dose Radiotherapy is highly effective in the Treatment of Patients with painful Ankle Arthrosis. In *Proceedings of STRAHLENTHERAPIE UND ONKOLOGIE*; pp. S188-S188. (DEGRO 2021)
3. Weissmann, T.; Gaipl, U.; Putz, F.; Hecht, M.; Donaubaue, A.-J.; Zhou, J.-G.; Fietkau, R.; Ott, O.; Frey, B. Low-Dose Radiotherapy is highly effective in the Treatment of painful Finger Polyarthrosis. In *Proceedings of STRAHLENTHERAPIE UND ONKOLOGIE*; pp. S57-S57. (DEGRO 2021)
4. Schweizer, C.; Haderlein, M.; Schubert, P.; Zhou, J.-G.; Semrau, S.; Rutzner, S.; Gostian, A.-O.; Frey, B.; Donaubaue, A.-J.; Eckstein, M. Prospective Assessment of the Inflammation Parameters in Blood Counts and Blood Serum as prognostic/predictive Parameters for Treatment with Immune Checkpoint-Inhibitors. In *Proceedings of STRAHLENTHERAPIE UND ONKOLOGIE*; pp. S48-S48. (DEGRO 2021)
5. Schubert, P.; Schweizer, C.; Roesch, J.; Haderlein, M.; Rutzner, S.; Semrau, S.; Donaubaue, A.; Zhou, J.; Frey, B.; Rainer, F. Progress Patterns under Radioimmunotherapy-clinical Evaluation of the prospective STICI Study. In *Proceedings of STRAHLENTHERAPIE UND ONKOLOGIE*; pp. S175-S176. (DEGRO 2021)



6. Zhou, J.G.; Ma, H.; Gaip, U. 304P Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors. *Annals of Oncology* 2020, 31, S1361, doi:10.1016/j.annonc.2020.10.298. (ESMO 2020)
7. Zhou, J.G.; Donaubaue, A.J.; Frey, B.; Becker, I.; Rutzner, S.; Eckstein, M.; Sun, R.; Ma, H.; Schubert, P.; Schweizer, C., et al. 302MO Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors. *Annals of Oncology* 2020, 31, S1360, doi:10.1016/j.annonc.2020.10.296. (ESMO Asia 2020)
8. Zhou, J.; Donaubaue, A.-J.; Frey, B.; Becker, I.; Rutzner, S.; Sun, R.; Ma, H.; Fietkau, R.; Deutsch, E.; Hecht, M. Development of an immunological prognostic Signature in metastatic Patients who were treated with Immune Checkpoint Inhibitors as part of the ST-ICI Study. In *Proceedings of STRAHLENTHERAPIE UND ONKOLOGIE*; pp. S27-S28. (DEGRO 2020)
9. Schubert, P.; Schweizer, C.; Roesch, J.; Haderlein, M.; Rutzner, S.; Semrau, S.; Donaubaue, A.-J.; Zhou, J.-G.; Frey, B.; Fietkau, R. Effectiveness of ablative Irradiation of all Metastases versus Irradiation of a singular Metastasis in Combination with Immunocheckpoint Inhibitors-clinical Evaluation of prospective STICI Study. In *Proceedings of STRAHLENTHERAPIE UND ONKOLOGIE*; pp. S171-S171. (DEGRO 2020)
10. Zhou, J.G.; Jin, S.H.; Ma, H. 235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study. *Annals of Oncology* 2019, 30, ix81, doi:https://doi.org/10.1093/annonc/mdz426.011. (ESMO Asia 2019)

PRESENTATIONS AND INVITED LECTURES

1. **Oral Presentation**, Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma, **EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY 2021 (14TH Meeting)**, SEPTEMBER 19 - 22, 2019; LYON, FRANCE.
2. **Mini Oral Presentation**, Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis of randomized controlled trials, **ESMO ASIA CONGRESS 2019**, 22 - 24 Nov 2019, Singapore, Republic of Singapore.
3. **Oral Presentation**, Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors, **KSMO 2021 VIRTUAL (13th Annual Meeting & 2020 International Conference; The Korean Society of Medical Oncology; 8th International FACO Conference)**, SEPTEMBER 3-4, 2020, SEOUL, KOREA.
4. **Mini Oral Presentation**, Identification of nine lncRNAs signature for predicting survival



benefit of melanoma patients treated with immune checkpoint inhibitors, **ESMO ASIA VIRTUAL CONGRESS 2020**, 20 - 22 Nov 2020, Singapore, Republic of Singapore.

5. Proffered Paper Oral Presentation, 30 - Identification of an endogenous retroviral signature to predict PD-1 blockade response in advanced clear cell renal cell carcinoma: Integrated analysis of 3 clinical trials, **ESMO Immuno-Oncology Congress 2021**, Dec 08-11, 2021; Geneva, Switzerland.

PROFESSIONAL TRAINING

Seminar or Workshop

1. Early Phase Clinical Trials Methodology For Drug Development In Oncology

CSCO, USCACA, ECCO, Shanghai, Dec 7-8, 2018

Description: Phase I Cancer Trial Methodologies, Trial design, Sample size analysis, dose analysis, etc.

2. Virtual Summer School in Translational Cancer Research

Cancer Core Europe (CCE), National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Oct 13-14, 2021

Description: Hallmarks of Cancer, Computational analysis of cancer genomes, Workshop Fundamentals of Scientific Writing: Publications and Proposals, etc.

3. SITC 2020 Grant Writing Workshop

SITC's Early Career Scientist Committee, Virtual, Nov 10, 2020

Description: an overview of the grant submission process, briefly outlining funding opportunities and the principles of grant writing.

4. The SITC-NCI Computational Immuno-Oncology Online Education Series

SITC, NCI, the SITC Big Data and Data Sharing Committee, Virtual, 2021-2022

Description: help advance my training in computational immuno-oncology and stay abreast of the latest technologies in this space.

5. SEER Variables, SEER and SEER*Stat Overview, etc.

NCI, Virtual, 2021

Description: update the new features of SEER and SEER*Stat, Methodologies.

Certification



1. Good Clinical Practice (GCP) Clinical Research Coordinator (CRC) Training Certification (No. 201703170), Affiliated Hospital of Zunyi Medical University, Aug 30- Sep 2, 2017.

Description: CRC is a person responsible for conducting clinical trials using GCP under the auspices of a Principal Investigator (PI).

2. GCP Quality Assurance in Clinical Trials Certification (No. 201801075), Affiliated Hospital of Zunyi Medical University, Jan 4-6, 2018.

Description: provided to help investigators conduct clinical studies on investigational new drugs comply with China law and regulations covering good clinical practice (GCP).

PROFESSIONAL AFFILIATIONS

1. Second Affiliated Hospital of Zunyi Medical University, 2017-Present

Attending physician and senior scientist (Master thesis supervisor) in the Department of Oncology.

2. Universitätsklinikum Erlangen, 2019-Present

PhD candidate and scientist in the Radiation Immunobiology Group (Prof. Dr. Udo Gaipl), Department of Radiation Oncology.

PROFESSIONAL SERVICE

Editors

since 2021	Associate Editor of Technology in Cancer Research & Treatment
since 2020	Academic Editor of Pain Research and Management
since 2020	Academic Editor of Disease Markers
since 2019	Academic Editor of Medicine®
since 2019	Guest associate editor of Frontiers in Oncology
since 2020	Guest associate editor of Frontiers in Genetics/ Frontiers in Immunology
since 2020	Guest associate editor of Cancer Control
2020	Guest editor of Contrast Media & Molecular Imaging

Peer-Reviewed Articles for:

More than 20 international Journals, e.g. Journal for ImmunoTherapy of Cancer, Oncoimmunology, Gynecologic Oncology, International Journal of Cancer, Clinical and Translational Medicine, Journal of experimental & clinical cancer research, Clinical Nutrition, et al.



LANGUAGES

List the languages that you know, along with your level of proficiency. Use an appropriate proficiency scale such as the ACTFL which provides guidelines for Novice, Intermediate, Advanced, Superior, and Distinguished levels in Listening, Speaking, Reading, and Writing.

Chinese: Native Language

English: Intermediate Listener, Novice Speaker, Advanced Reading and Writing

COMPUTER SKILLS

It may be useful to provide a summary of your relevant skills, such as your computer skills. You could list your skills using a consistent format such as

Programming: R, STATA, PYTHON, etc.

Applications: Rstudio, Jupyter, etc.

Platforms: Mac, Linux, Win.

OTHER

Interests/Hobbies worth noting: Hiking, fitness, reading.
Citizenship: the People's Republic of China